You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company, which launched the technology in September 2019, said in its Q4 earnings release that it received high marks from beta testers.
The agreement marks Veracyte's first deal to expand the testing menu on the nCounter instrument since it acquired the rights to the platform from NanoString in December.
The partners are planning to develop and commercialize UroMap, a urine-based gene-expression test for acute cellular rejection in kidney transplant recipients.
The company reported $38.4 million in total revenues for the quarter and said testing services revenues rose 46 percent year over year.
The ALARM Partnership is being launched to measure the impact of AlloSure and RemoTraC on lung transplant patients.
The plaintiffs allege that TAI's heart transplant rejection test MyTAIHeart infringes on their patent for the non-invasive diagnosis of graft rejection.
The company said the COVID-19 pandemic and resulting stay-at-home orders have led to a slowdown in testing service volumes in recent weeks.
The company's original lawsuit, filed last March, accused Natera of infringing on two patents it holds in conjunction with Stanford University.
The company said testing revenues rose 54 percent during the quarter, and that it provided 63 percent more patient results year over year.
CareDx first sued Natera in April 2019, accusing the company of trying to mislead patients and clinicians about the superiority of its Prospera transplant test.